PMID- 31294371
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220409
IS  - 2515-2092 (Electronic)
IS  - 2515-2084 (Print)
IS  - 2515-2084 (Linking)
VI  - 2
IP  - 2
DP  - 2019 May
TI  - Long-Term Effectiveness, Safety and Mortality Associated with the Use of TC-325 
      for Malignancy-Related Upper Gastrointestinal Bleeds: A Multicentre Retrospective 
      Study.
PG  - 91-97
LID - 10.1093/jcag/gwy031 [doi]
AB  - BACKGROUND AND STUDY AIMS: Malignant-related upper gastrointestinal bleeding 
      (MRUGIB) is difficult to treat by conventional endoscopic methods. We sought to 
      determine the efficacy, safety and mortality associated with the use of TC-325 
      for the treatment of MUGIB. PATIENTS AND METHODS: This is a multicentre, 
      retrospective study at the University of Calgary and University of Ottawa 
      performed between January 1, 2010, and July 30, 2016. TC-325 use was identified 
      via staff polling, product order forms and endoscopic records review. Once 
      identified, patient charts and online records were examined to identify MRUGIB 
      cases and to assess our primary and secondary endpoints. OUTCOMES: The primary 
      outcome was hemostasis at seven days. Secondary outcomes include immediate 
      hemostasis, early hemostasis, hemostasis at 14 days, 30-day mortality, adverse 
      events related to TC-325 therapy and the need for repeat endoscopic intervention, 
      surgery or transarterial embolization. RESULTS: Twenty-five patients were 
      identified. The median age was 62 years (interquartile range [IQR] 52.5-76), and 
      most were male (64%). TC-325 was the primary treatment modality in 20 patients 
      (80%). Hemostasis was 88%, 89%, 58% and 50% at 24 hours, 72 hours, 7 days and 14 
      days, respectively. Five patients underwent repeat endoscopy, two patients 
      required surgical intervention, and transarterial embolization was not required. 
      Twelve patients died by 30 days (48%). There were no complications directly 
      attributed to the use of TC-325. CONCLUSIONS: TC-325 is effective for achieving 
      and maintaining hemostasis in patients with malignancy-related upper 
      gastrointestinal bleeding, and most patients do not require additional 
      interventions. The 30-day mortality risk in this group of patients is high.
FAU - Meng, Zhao Wu
AU  - Meng ZW
AUID- ORCID: 0000-0003-3589-2208
AD  - Department of Medicine, University of Ottawa, Ottawa, Canada.
FAU - Marr, Kaleb J
AU  - Marr KJ
AD  - Department of Medicine, University of Calgary, Calgary, Canada.
FAU - Mohamed, Rachid
AU  - Mohamed R
AD  - Department of Medicine, University of Calgary, Calgary, Canada.
FAU - James, Paul D
AU  - James PD
AD  - Department of Medicine, University of Ottawa, Ottawa, Canada.
AD  - Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada.
AD  - Department of Medicine, University Health Network, University of Toronto, 
      Toronto, Canada.
LA  - eng
PT  - Journal Article
DEP - 20180711
PL  - England
TA  - J Can Assoc Gastroenterol
JT  - Journal of the Canadian Association of Gastroenterology
JID - 101738684
PMC - PMC6507283
OTO - NOTNLM
OT  - Malignancy-related upper gastrointestinal bleeds
OT  - TC-325
EDAT- 2019/07/12 06:00
MHDA- 2019/07/12 06:01
PMCR- 2018/07/11
CRDT- 2019/07/12 06:00
PHST- 2019/07/12 06:00 [entrez]
PHST- 2019/07/12 06:00 [pubmed]
PHST- 2019/07/12 06:01 [medline]
PHST- 2018/07/11 00:00 [pmc-release]
AID - gwy031 [pii]
AID - 10.1093/jcag/gwy031 [doi]
PST - ppublish
SO  - J Can Assoc Gastroenterol. 2019 May;2(2):91-97. doi: 10.1093/jcag/gwy031. Epub 
      2018 Jul 11.